Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
INCLISIRAN SODIUM, BEMPEDOIC ACID, ATORVASTATIN, ROSUVASTATIN, EZETIMIBE
Novartis Ophthalmics Europe
Hypercholesterolemia
1 trial -
IPTACOPAN HYDROCHLORIDE, IPTACOPAN
Novartis Ophthalmics Europe
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
1 trial -
Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 20 mg tablets, Jakavi 5 mg tablets, HDM201, RUXOLITINIB, Jakavi 20 mg tablets, Farydak 15 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 5 mg tablets, Farydak 10 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, HDM201, Jakavi 20 mg tablets
Novartis Ophthalmics Europe
This study is designed to accept patients with varied disease origins, depending on the parent protocol
1 trial -
Kesimpta 20 mg solution for injection in pre-filled syringe
Novartis Ophthalmics Europe
Relapsing forms of Multiple Sclerosis (RMS)
1 trial -
LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN
Novartis Ophthalmics Europe
HR+, HER2- advanced or metastatic breast cancer
1 trial -
Mekinist, DRB436, DRB436, TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, DRB436, Mekinist 2 mg film-coated tablets
Novartis Ophthalmics Europe
Children and Adolescents with Cancers Harboring V600 mutation.
1 trial -
Placebo to AIN457 150 mg/1 mL Solution for injection in pre-filled syringe, SECUKINUMAB
Novartis Ophthalmics Europe
non-radiographic axial spondyloarthritis
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion
Novartis Ophthalmics Europe
Prostate cancer
1 trial -
ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, INCLISIRAN
Novartis Ophthalmics Europe
Hypercholesterolemia
1 trial -
SEG101
Novartis Ophthalmics Europe
Sickle cell disease
1 trial -
TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, Mekinist 2 mg film-coated tablets, DRB436, DRB436, DRB436, TMT212
Novartis Ophthalmics Europe
Multiple indications
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources